Do all GLP-1 drugs affect oral contraceptives?

No. The reported effect is tirzepatide-specific; semaglutide, liraglutide and dulaglutide did not show it.

Why does tirzepatide differ?

It engages the GIP receptor as well as GLP-1 and produces a greater reported delay in gastric emptying, which affects absorption of anything taken by mouth alongside it.

Why does the label mention dose escalation?

The gastric emptying delay is largest when a dose is new and attenuates with continued exposure, so each escalation reintroduces it.

GLP-1 & Incretin Science

One Compound, Not the Whole Class

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Reported data show a single 5 mg tirzepatide dose reducing peak concentrations of ethinyl estradiol, norgestimate and norelgestromin by 59%, 66% and 55% respectively, with overall exposure down around 20%. Semaglutide, liraglutide and dulaglutide did not show this effect.

Key facts

Compound affected: Tirzepatide
Ethinyl estradiol peak: Reduced ~59%
Norgestimate peak: Reduced ~66%
Norelgestromin peak: Reduced ~55%
Overall exposure: Down ~20%
Not affected: Semaglutide, liraglutide, dulaglutide
Review: Skelley 2024 (PMID 37940101)

Why one compound behaves differently

Tirzepatide engages the GIP receptor as well as GLP-1, and the reported effect on gastric emptying is greater than that of the pure GLP-1 agonists. A larger delay in gastric emptying produces a larger effect on the absorption of anything taken by mouth alongside it, so the interaction tracks the magnitude of the underlying pharmacology.

Why dose escalation compounds it

Delayed gastric emptying attenuates with continued exposure at a stable dose — the effect is largest when a dose is new. A regimen that steps up through several doses therefore reintroduces a strong delay each time it escalates, rather than producing one adaptation that then settles. That is why the reported label position attaches to escalations and not only to starting.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The gap between peak and total, and why it matters here

Peak concentrations fell by 55 to 66% while overall exposure fell by around 20%. That gap is the signature of an absorption-rate effect rather than a loss of drug. For a hormonal contraceptive, though, this is precisely the case where the peak is not merely cosmetic, which is why the finding attracted labelling attention rather than being noted and set aside.

What the label position is

The FDA labelling directs that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method for four weeks after initiation and for four weeks after each dose escalation. That is a statement of what a regulator has required on a label, reported here as a fact about the label. It is not advice, and decisions of this kind belong with a prescriber.

Why treating this as a class property is the common error

Coverage of GLP-1 drug interactions generally speaks about the class as a unit. Skelley and colleagues examined tirzepatide alongside the GLP-1 receptor agonists in the Journal of the American Pharmacists Association in 2024, and the finding is a contrast rather than a shared property. Applying tirzepatide's interaction profile to semaglutide overstates it; applying semaglutide's to tirzepatide understates it.

The boundary

Tirzepatide and the other compounds named are licensed medicines. Nothing supplied on this site is any of them, is related to them, or interacts with any medicine a person may be taking, because nothing here is for human use in any form.

Quick reference

Compound	Effect on oral contraceptive absorption
Tirzepatide	Peak reduced 55–66%; exposure down ~20%
Semaglutide	Not shown to affect bioavailability
Liraglutide	Not shown to affect bioavailability
Dulaglutide	Not shown to affect bioavailability

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Do all GLP-1 drugs affect oral contraceptives?: No. The reported effect is tirzepatide-specific; semaglutide, liraglutide and dulaglutide did not show it.
Why does tirzepatide differ?: It engages the GIP receptor as well as GLP-1 and produces a greater reported delay in gastric emptying, which affects absorption of anything taken by mouth alongside it.
Why does the label mention dose escalation?: The gastric emptying delay is largest when a dose is new and attenuates with continued exposure, so each escalation reintroduces it.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum